We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Asuragen Licenses Roche’s Real-time Quantitative PCR Technology for Clinical Gene Expression Profiling
News

Asuragen Licenses Roche’s Real-time Quantitative PCR Technology for Clinical Gene Expression Profiling

Asuragen Licenses Roche’s Real-time Quantitative PCR Technology for Clinical Gene Expression Profiling
News

Asuragen Licenses Roche’s Real-time Quantitative PCR Technology for Clinical Gene Expression Profiling

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Asuragen Licenses Roche’s Real-time Quantitative PCR Technology for Clinical Gene Expression Profiling"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Asuragen Pharmacogenomic Services has received a license from Roche Molecular Systems for clinical gene expression profiling and DNA analysis utilizing Roche's real-time quantitative PCR technology (qRT-PCR, qPCR). This agreement provides Asuragen access to intellectual property rights that broaden its clinical testing capabilities.

"As our bio-pharmaceutical clients move their testing out of discovery and into clinical research and trials, Asuragen is proud to be the first pharmacogenomic service provider to offer qRT-PCR assays for pharmaceutical drug trials," stated Scott Hunicke-Smith, General Manager of Asuragen Services.

With these newly acquired rights and Asuragen's recent CLIA registration, Asuragen’s robust microRNA and mRNA profiling services can be used to test predictive biomarker signatures, efficacy markers, and patient stratification tests during clinical and drug trials.

Asuragen Services offers a full range of clinical services including: assay design, development, and validation, FFPE and PAXgene® blood RNA isolation, and QC testing. Asuragen also conducts biomarker bridging studies from fresh to FFPE tissues and from array to qRT-PCR assay.

Advertisement